Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

5.66USD
24 Feb 2017
Change (% chg)

$-0.05 (-0.88%)
Prev Close
$5.71
Open
$5.69
Day's High
$5.74
Day's Low
$5.66
Volume
1,355
Avg. Vol
5,863
52-wk High
$6.52
52-wk Low
$4.20

CPIX.OQ

Chart for CPIX.OQ

About

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcyste... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $91.58
Shares Outstanding(Mil.): 16.18
Dividend: --
Yield (%): --

Financials

  CPIX.OQ Industry Sector
P/E (TTM): -- 28.84 29.63
EPS (TTM): -0.00 -- --
ROI: -0.13 13.44 12.96
ROE: -0.06 14.34 14.11

Cumberland defeats Mylan’s appeal on Acetadote patent

A federal appeals court on Thursday dealt another blow to Mylan Inc’s plans to offer a generic version of an improved antidote for acetaminophen poisoning, ruling that Cumberland Pharmaceutical’s patent on the product was valid.

Jan 27 2017

BRIEF-Cumberland Pharmaceuticals, Clinigen enter U.S. commercialization agreement for Totect

* Cumberland pharmaceuticals and Clinigen enter exclusive U.S. commercialization agreement for Totect

Jan 09 2017

BRIEF-Cumberland Pharmaceuticals acquires U.S. rights to Nordic Group's methotrexate injection products

* Says it will register and commercialize methotrexate products in United States

Nov 16 2016

BRIEF-Cumberland Pharmaceuticals Q3 earnings per share $0.01

* Cumberland Pharmaceuticals reports third quarter & year to date 2016 financial results

Nov 01 2016

BRIEF-Clinigen and Cumberland Pharmaceuticals launch dry mouth drug in U.S

* Clinigen GrouE and Cumberland Pharmaceuticals launch Rthyol in U.S Source text for Eikon: Further company coverage:

Sep 26 2016

BRIEF-Cumberland reports new program to develop Portaban for Portal Hypertension

* Cumberland Pharmaceuticals announces new program to develop Portaban for Portal Hypertension

Sep 14 2016

More From Around the Web

Earnings vs. Estimates